Ramucirumab/Durvalumab Combination Shows Antitumor Activity in Gastric and GEJ Cancer
January 19th 2018The combination of the VEGFR-2 inhibitor ramucirumab plus the anti-PD-L1 agent durvalumab demonstrated antitumor activity in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma.
Read More